Sarepta Therapeutics, Inc. short interest in 2024
In 2024, Sarepta Therapeutics, Inc.'s disclosed short interest ran from 6.07% of shares outstanding on 12 Jan 2024 to 5.37% on 31 Dec 2024, a change of -0.70 percentage points. The year's high was 10.11% on 28 Jun 2024 and its low 4.91% on 28 Mar 2024, averaging 6.39% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.23 days on 30 Aug 2024. Full history: Sarepta Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 6.07% (12 Jan 2024)
- End of year
- 5.37% (31 Dec 2024)
- Change
- -0.70 pp
- High
- 10.11% (28 Jun 2024)
- Low
- 4.91% (28 Mar 2024)
- Average
- 6.39%
- Highest days to cover
- 9.23 (30 Aug 2024)
- SEC filings marked
- 5
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 6.07% | 3.25 | results (8-K) |
| 31 Jan 2024 | 5.53% | 4.41 | |
| 15 Feb 2024 | 5.14% | 6.09 | |
| 29 Feb 2024 | 5.11% | 4.15 | 10-K filed |
| 15 Mar 2024 | 5.31% | 5.10 | |
| 28 Mar 2024 | 4.91% | 7.90 | |
| 15 Apr 2024 | 5.21% | 7.99 | |
| 30 Apr 2024 | 6.02% | 6.18 | |
| 15 May 2024 | 6.94% | 5.38 | 10-Q filed |
| 31 May 2024 | 6.87% | 2.25 | |
| 14 Jun 2024 | 10.01% | 7.04 | |
| 28 Jun 2024 | 10.11% | 2.71 | |
| 15 Jul 2024 | 7.76% | 5.90 | |
| 31 Jul 2024 | 7.11% | 6.12 | |
| 15 Aug 2024 | 7.06% | 4.33 | 10-Q filed |
| 30 Aug 2024 | 6.85% | 9.23 | |
| 13 Sep 2024 | 6.45% | 7.42 | |
| 30 Sep 2024 | 6.49% | 9.10 | |
| 15 Oct 2024 | 5.93% | 6.54 | |
| 31 Oct 2024 | 5.87% | 8.01 | |
| 15 Nov 2024 | 5.28% | 3.88 | 10-Q filed |
| 29 Nov 2024 | 6.09% | 3.87 | |
| 13 Dec 2024 | 5.85% | 8.03 | |
| 31 Dec 2024 | 5.37% | 7.48 |
See also: Sarepta Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.